III期-话题@MedSci

#III期#

681篇内容 | 2818人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594827, encodeId=5456159482e1d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎, objectType=article, longId=202989, objectId=b8be20298966, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8be20298966, replyNumber=0, likeNumber=13, createdTime=2020-11-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8be20298966, moduleTitle=诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8be20298966)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594826, encodeId=d00e159482648, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=中国批准国产阿尔茨海默症早诊示踪剂进入III期临床, objectType=article, longId=202931, objectId=45b2202931e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45b2202931e6, replyNumber=0, likeNumber=71, createdTime=2020-11-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45b2202931e6, moduleTitle=中国批准国产阿尔茨海默症早诊示踪剂进入III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45b2202931e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594825, encodeId=da431594825d8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市, objectType=article, longId=202883, objectId=f95120288352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f95120288352, replyNumber=0, likeNumber=71, createdTime=2020-11-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f95120288352, moduleTitle=默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f95120288352)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594824, encodeId=7b9b1594824b1, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lancet oncol：临床试验15年随访结果：放疗对I-III期乳腺癌预后的影响, objectType=article, longId=202875, objectId=fa6b2028e5d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa6b2028e5d2, replyNumber=0, likeNumber=63, createdTime=2020-11-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa6b2028e5d2, moduleTitle=Lancet oncol：临床试验15年随访结果：放疗对I-III期乳腺癌预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa6b2028e5d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594823, encodeId=756515948236e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验, objectType=article, longId=202718, objectId=5865202e1851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5865202e1851, replyNumber=0, likeNumber=79, createdTime=2020-11-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5865202e1851, moduleTitle=Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5865202e1851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594822, encodeId=e39f159482268, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验, objectType=article, longId=202653, objectId=fcf72026535d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcf72026535d, replyNumber=0, likeNumber=15, createdTime=2020-10-31, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcf72026535d, moduleTitle=NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcf72026535d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594821, encodeId=eb381594821da, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, objectType=article, longId=202599, objectId=ad7320259999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad7320259999, replyNumber=0, likeNumber=14, createdTime=2020-10-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad7320259999, moduleTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad7320259999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594820, encodeId=4e991594820f1, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Clin Oncol：III期SORCE | 索拉非尼不能用作中高复发风险的原发肾癌的术后辅助治疗, objectType=article, longId=202290, objectId=28a7202290f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28a7202290f1, replyNumber=0, likeNumber=45, createdTime=2020-10-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28a7202290f1, moduleTitle=J Clin Oncol：III期SORCE | 索拉非尼不能用作中高复发风险的原发肾癌的术后辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28a7202290f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594819, encodeId=8c091594819ce, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率, objectType=article, longId=202204, objectId=7085202204a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7085202204a8, replyNumber=0, likeNumber=60, createdTime=2020-10-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7085202204a8, moduleTitle=III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7085202204a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594818, encodeId=1e5b15948183f, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=基因治疗IIIA型粘多糖贮积症的II/III期研究中，一名患者死亡, objectType=article, longId=202184, objectId=2910202184d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2910202184d2, replyNumber=0, likeNumber=50, createdTime=2020-10-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2910202184d2, moduleTitle=基因治疗IIIA型粘多糖贮积症的II/III期研究中，一名患者死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2910202184d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594817, encodeId=f016159481e9c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Zeposia（ozanimod）治疗中重度溃疡性结肠炎成年患者：III期研究取得突破性进展, objectType=article, longId=202039, objectId=6aa0202039eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aa0202039eb, replyNumber=0, likeNumber=77, createdTime=2020-10-14, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aa0202039eb, moduleTitle=Zeposia（ozanimod）治疗中重度溃疡性结肠炎成年患者：III期研究取得突破性进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aa0202039eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594816, encodeId=66ae1594816da, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性, objectType=article, longId=201999, objectId=9dcd20199981, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dcd20199981, replyNumber=0, likeNumber=68, createdTime=2020-10-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dcd20199981, moduleTitle=瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dcd20199981)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594815, encodeId=4d421594815dc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败, objectType=article, longId=201995, objectId=a7e920199565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7e920199565, replyNumber=0, likeNumber=80, createdTime=2020-10-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7e920199565, moduleTitle=免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7e920199565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594814, encodeId=f932159481419, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=单抗III期临床试验失败案例及原因分析, objectType=article, longId=201985, objectId=5e8f20198506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e8f20198506, replyNumber=0, likeNumber=116, createdTime=2020-10-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e8f20198506, moduleTitle=单抗III期临床试验失败案例及原因分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e8f20198506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594813, encodeId=bf761594813fc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=GSk/Vir Biotechnology中和抗体治疗早期COVID-19进入III期阶段, objectType=article, longId=201860, objectId=7aa320186063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7aa320186063, replyNumber=0, likeNumber=50, createdTime=2020-10-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7aa320186063, moduleTitle=GSk/Vir Biotechnology中和抗体治疗早期COVID-19进入III期阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7aa320186063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594812, encodeId=6098159481298, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=GSK和Vir Biotechnology将抗SARS-CoV-2单克隆抗体推荐到III期临床, objectType=article, longId=201817, objectId=ab3520181ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab3520181ee0, replyNumber=0, likeNumber=0, createdTime=2020-10-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab3520181ee0, moduleTitle=GSK和Vir Biotechnology将抗SARS-CoV-2单克隆抗体推荐到III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab3520181ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594811, encodeId=c13f1594811a5, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Xevinapant治疗头颈癌：步入大型III期临床试验, objectType=article, longId=201506, objectId=3857201506d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3857201506d7, replyNumber=0, likeNumber=62, createdTime=2020-10-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3857201506d7, moduleTitle=Xevinapant治疗头颈癌：步入大型III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3857201506d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594810, encodeId=6cd11594810bc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？, objectType=article, longId=201486, objectId=14fc201486bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14fc201486bd, replyNumber=0, likeNumber=62, createdTime=2020-10-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14fc201486bd, moduleTitle=强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14fc201486bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594809, encodeId=2aaf15948099e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, objectType=article, longId=201382, objectId=2172201382b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2172201382b6, replyNumber=0, likeNumber=35, createdTime=2020-10-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2172201382b6, moduleTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2172201382b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594808, encodeId=5592159480859, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=APL-106治疗急性骨髓性白血病：将启动III期桥接研究, objectType=article, longId=201356, objectId=ba0c201356f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba0c201356f9, replyNumber=0, likeNumber=0, createdTime=2020-09-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba0c201356f9, moduleTitle=APL-106治疗急性骨髓性白血病：将启动III期桥接研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba0c201356f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺华的IL-17A单抗Cosentyx在银屑病关节炎III期研究中显著减轻滑膜炎

2020-11-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

中国批准国产阿尔茨海默症早诊示踪剂进入III期临床

2020-11-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市

2020-11-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lancet oncol：临床试验15年随访结果：放疗对I-III期乳腺癌预后的影响

2020-11-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验

2020-11-02

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验

2020-10-31

智智灵药 (审核中...)

前往app查看评论内容

#III期#

拜耳Finerenone FIDELIO-DKD III期临床研究结果公布

2020-10-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Clin Oncol：III期SORCE | 索拉非尼不能用作中高复发风险的原发肾癌的术后辅助治疗

2020-10-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期数据证明：IL-23单抗TREMFYA可连续5年，维持斑块状牛皮癣患者的皮肤清除率

2020-10-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

基因治疗IIIA型粘多糖贮积症的II/III期研究中，一名患者死亡

2020-10-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Zeposia（ozanimod）治疗中重度溃疡性结肠炎成年患者：III期研究取得突破性进展

2020-10-14

智智灵药 (审核中...)

前往app查看评论内容

#III期#

瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性

2020-10-13

智智灵药 (审核中...)

前往app查看评论内容

#III期#

免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败

2020-10-13

智智灵药 (审核中...)

前往app查看评论内容

#III期#

单抗III期临床试验失败案例及原因分析

2020-10-13

智智灵药 (审核中...)

前往app查看评论内容

#III期#

GSk/Vir Biotechnology中和抗体治疗早期COVID-19进入III期阶段

2020-10-10

智智灵药 (审核中...)

前往app查看评论内容

#III期#

GSK和Vir Biotechnology将抗SARS-CoV-2单克隆抗体推荐到III期临床

2020-10-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Xevinapant治疗头颈癌：步入大型III期临床试验

2020-10-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？

2020-10-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著

2020-10-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

APL-106治疗急性骨髓性白血病：将启动III期桥接研究

2020-09-30

科室
- - 订阅+
  - 更多科室
工具
服务